18 November 2021 | News
Ginkgo's synthetic biology platform infrastructure and expertise brings critical capability to Victoria's biotech sector
image credit- shutterstock
mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and US-based Ginkgo Bioworks, has announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia.
As the first step in the partnership, Ginkgo will establish an office in Melbourne in what is hoped to be a future long-term business expansion within Australia.
Ginkgo's synthetic biology platform infrastructure and expertise brings critical capability to Victoria's biotech sector, and adds significant momentum to the State's rapidly growing biotechnology ecosystem.
Ginkgo's cell programming capabilities have supported innovations in diagnostics and vaccine design and manufacturing, as well as ongoing research and development of innovative products such as living medicines, therapeutic proteins, and gene and cell therapies.
Victoria is a leader in mRNA research and manufacturing in Australia, with the nation's most sophisticated and largest mRNA ecosystem and commercialization capability. Through mRNA Victoria, the Victorian Government will continue to attract world leading biotech innovators to invest in Victoria, creating new jobs and fostering innovation in novel RNA treatments.